作者更正：具有完全人源仅重链抗原识别结构域的抗BCMA嵌合抗原受体
Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
作者信息
Lam Norris, Trinklein Nathan D, Buelow Benjamin, Patterson George H, Ojha Namrata, Kochenderfer James N
机构信息
National Institutes of Health, National Cancer Institute, Center for Cancer Research, Surgery Branch, NIH Building 10 Room 3-3888, Bethesda, MD, 20892, USA.
TeneoBio, Inc., 7999 Gateway Blvd, Newark, CA, 94560, USA.
出版信息
Nat Commun. 2020 Mar 9;11(1):1319. doi: 10.1038/s41467-020-15145-8.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
摘要
本文的一个修订版本已发表，可通过本文顶部的链接获取。
相似文献
1
Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.作者更正：具有完全人源仅重链抗原识别结构域的抗BCMA嵌合抗原受体
Nat Commun. 2020 Mar 9;11(1):1319. doi: 10.1038/s41467-020-15145-8.
2
Author Correction: A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.作者更正：一种通过计算设计的嵌合抗原受体为T细胞疗法提供了一种小分子安全开关。
Nat Biotechnol. 2020 Apr;38(4):503. doi: 10.1038/s41587-020-0461-z.
3
Author Correction: Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.作者更正：重新利用内源性免疫途径来定制和控制嵌合抗原受体T细胞功能。
Nat Commun. 2020 May 7;11(1):2357. doi: 10.1038/s41467-020-16301-w.
4
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.作者更正：具有完全人源化结合结构域的抗CD19嵌合抗原受体T细胞在B细胞淋巴瘤患者中的安全性和可行性。
Nat Med. 2020 May;26(5):803. doi: 10.1038/s41591-020-0864-x.
5
Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 cytotoxic T lymphocytes against multiple myeloma: clinical applications.更正：BCMA肽工程纳米颗粒增强针对多发性骨髓瘤的抗原特异性CD8细胞毒性T淋巴细胞的诱导和功能：临床应用
Leukemia. 2020 Jul;34(7):1971. doi: 10.1038/s41375-020-0705-4.
6
Author Correction: Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.作者更正：2'-氟修饰的嵌合反义寡核苷酸介导的外显子跳跃的体外系统评价。
Sci Rep. 2020 Apr 16;10(1):6669. doi: 10.1038/s41598-020-63706-0.
7
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
8
Author Correction: Bidirectional regulatory potentials of short-chain fatty acids and their G-protein-coupled receptors in autoimmune neuroinflammation.作者更正：短链脂肪酸及其G蛋白偶联受体在自身免疫性神经炎症中的双向调节潜力。
Sci Rep. 2019 Nov 20;9(1):17511. doi: 10.1038/s41598-019-54276-x.
9
Author Correction: Chimeric peptidomimetic antibiotics against Gram-negative bacteria.作者更正：针对革兰氏阴性菌的嵌合拟肽抗生素。
Nature. 2019 Dec;576(7786):E5. doi: 10.1038/s41586-019-1810-2.
10
Author Correction: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.作者更正：共抑制受体的阴阳平衡：迈向无自身免疫的抗肿瘤免疫
Cell Res. 2020 Apr;30(4):366. doi: 10.1038/s41422-020-0285-x.
引用本文的文献
1
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.用于治疗慢性淋巴细胞白血病患者的抗CD19嵌合抗原受体T细胞生产的优化
Mol Ther Methods Clin Dev. 2024 Feb 13;32(1):101212. doi: 10.1016/j.omtm.2024.101212. eCollection 2024 Mar 14.
2
NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment.表达抗 BCMA CAR 和 TRAIL 的 NK92 细胞用于多发性骨髓瘤的治疗：初步体外评估。
Cells. 2023 Nov 30;12(23):2748. doi: 10.3390/cells12232748.
Zotero 插件